Completed PHASE1 INTERVENTIONAL NCT00398450

Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma

A Phase I Study of 5-azacytidine (Vidaza) With Interferon α2b in Metastatic Melanoma Patients

Sponsor: National Cancer Institute (NCI)

Interventions azacitidine recombinant interferon alfa-2b

Updated 6 times since 2017 Last updated: Mar 1, 2021 Started: Feb 28, 2006 Primary completion: Apr 30, 2010 Completion: Apr 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00398450, this PHASE1 trial focuses on Melanoma (Skin) and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 6 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Apr 2021 — Jul 2024 [monthly]

Completed PHASE1

Status: Unknown Status → Completed
Jan 2021 — Apr 2021 [monthly]

Unknown Status PHASE1
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE1

First recorded

Feb 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
University of California, San Diego

Data source: University of California, San Diego

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• La Jolla, United States